


Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-E55F42F8-8E2A-4536-A5EB-FB62EA29CFE4\_6\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M33310\\_06\\_01](https://doi.org/10.31003/USPNF_M33310_06_01)  
DOI Ref: ng941

© 2025 USPC  
Do not distribute

## Fludarabine Phosphate



$C_{10}H_{13}FN_5O_7P$  365.21

9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-;  
9-β-D-Arabinofuranosyl-2-fluoroadenine 5'-dihydrogen phosphate CAS RN®: 75607-67-9; UNII: 1X9VK901SC.

### DEFINITION

Fludarabine Phosphate contains NLT 98.0% and NMT 102.0% of fludarabine phosphate ( $C_{10}H_{13}FN_5O_7P$ ), calculated on the anhydrous, solvent-free basis.

**CAUTION**—Fludarabine phosphate is potentially cytotoxic. Great care should be taken to prevent inhaling particles and exposing the skin to it.]

### IDENTIFICATION

**Change to read:**

- A. ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197A or 197K▲ (CN 1-May-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Solution A:** 10 mM [monobasic potassium phosphate](#)

**Mobile phase:** [Methanol](#) and *Solution A* (6:94)

**Standard solution:** 0.02 mg/mL of [USP Fludarabine Phosphate RS](#) in *Mobile phase*

**Sample solution:** 0.02 mg/mL of Fludarabine Phosphate in *Mobile phase*

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 260 nm

**Column:** 4.6-mm × 15-cm; 5-μm packing [L1](#)

**Flow rate:** 1.0 mL/min

**Injection volume:** 10 μL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Relative standard deviation:** NMT 1.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of fludarabine phosphate ( $C_{10}H_{13}FN_5O_7P$ ) in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response from the *Sample solution*

$r_s$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Fludarabine Phosphate RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Fludarabine Phosphate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the anhydrous, solvent-free basis

**IMPURITIES****• CHLORIDE****Standard stock solution:** 82.4 µg/mL of [sodium chloride](#) in [water](#)**Standard solution:** Transfer 2.0 mL of *Standard stock solution* to a test tube, add 13.0 mL of [water](#), and mix.**Sample solution:** Transfer 50.0 mg of Fludarabine Phosphate to a test tube, add 15 mL of water to dissolve, and heat gently if necessary.**Analysis:** Add 1.0 mL of [nitric acid](#) to the *Standard solution* and *Sample solution*, and place each in separate, colorless test tubes containing 1.0 mL of silver nitrate TS.**Acceptance criteria:** NMT 0.2%; the *Sample solution* shows less turbidity than the *Standard solution*.**• LIMIT OF FREE PHOSPHATE****Reagent solution:** Mix 4 g of finely powdered [ammonium molybdate](#) and 0.1 g of finely powdered [ammonium vanadate](#) in a 150-mL beaker.Add 70 mL of [water](#), and grind the particles using a glass rod. A clear solution is obtained within a few minutes. Add 20 mL of [nitric acid](#), adjust to room temperature, and dilute with [water](#) to 100 mL.**Standard solution:** 7.16 µg/mL of potassium dihydrogen phosphate in [water](#). Transfer 2.0 mL of this solution to a test tube.**Sample solution:** Transfer 10 mg of Fludarabine Phosphate in 2.0 mL of [water](#) to a test tube and heat gently.**Blank:** 2.0 mL of [water](#) in a test tube**Analysis:** To each of the test tubes containing the *Standard solution*, *Sample solution*, and *Blank*, add 2.0 mL of *Reagent solution*.**Acceptance criteria:** NMT 0.1%; the color of the *Standard solution* must be more intense than that of the *Blank*. Viewed downward in diffuse daylight against a white background, the yellow coloration of the *Sample solution* must not be more intense than that of the *Standard solution*.**• LIMIT OF SODIUM****Standard stock solution:** 2.54 mg/mL of [sodium chloride](#) in [water](#). [Sodium chloride](#) is previously dried at 105° for 2 h.**Standard solution:** 1 µg/mL of sodium in water, from *Standard stock solution***Sample solution:** 0.5 mg/mL of Fludarabine Phosphate in water**Instrumental conditions****Mode:** Flame photometry**Analytical wavelength:** Sodium emission line at 589.0 nm**Blank:** Water**Analysis****Samples:** *Standard solution* and *Sample solution***Acceptance criteria:** NMT 0.2%; the emission response of the *Sample solution* is NMT that of the *Standard solution*.**• ORGANIC IMPURITIES, PROCEDURE 1: EARLY-ELUTING IMPURITIES****Mobile phase, Standard solution, and Chromatographic system:** Proceed as directed in the Assay.**System suitability solution:** 10 mg of Fludarabine Phosphate in 10 mL of [0.1 N hydrochloric acid](#). Heat the solution at 80° in a water bath for 15 min.**Sensitivity solution:** 0.5 µg/mL of [USP Fludarabine Phosphate RS](#) in *Mobile phase*, from the *Standard solution***Sample solution:** 1 mg/mL of Fludarabine Phosphate in *Mobile phase***System suitability****Samples:** *Standard solution*, *System suitability solution*, and *Sensitivity solution***Suitability requirements****Resolution:** NLT 2.0 between the iso-ara-guanine monophosphate and isoguanine peaks, *System suitability solution***Relative standard deviation:** NMT 2.0%, *Standard solution***Signal-to-noise ratio:** NLT 10, *Sensitivity solution***Analysis****Sample:** *Sample solution*

Calculate the percentage of each early-eluting impurity in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_u/r_s) \times (1/F_1) \times 100$$

 $r_u$  = peak response of each individual impurity from the *Sample solution* $r_s$  = peak response of fludarabine phosphate from the *Sample solution* $F_1$  = relative response factor for each individual impurity (see [Table 1](#))**Acceptance criteria:** See [Table 1](#).**Table 1**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Iso-ara-guanine-monophosphate <sup>a</sup>	0.26	0.25	0.8
Isoguanine <sup>b</sup>	0.34	0.40	0.2
3',5'-Diphosphate analog <sup>c</sup>	0.42	0.53	0.4
Any individual, unspecified impurity	<1.0	1.0	0.1
Fludarabine phosphate	1.0	—	—

<sup>a</sup> 6-Amino-9-β-D-arabinofuranosyl-2-oxo-1*H*-purine 5'- (dihydrogen phosphate).

<sup>b</sup> 6-Amino-1*H*-purin-2(9*H*)-one.

<sup>c</sup> 9-β-D-Arabinofuranosyl-2-fluoroadenine 3',5'-bis(dihydrogen phosphate).

• **ORGANIC IMPURITIES, PROCEDURE 2: LATE-ELUTING IMPURITIES**

**Solvent A:** 10 mM [monobasic potassium phosphate](#)

**Mobile phase:** [Methanol](#) and Solvent A (1:4)

**Standard solution and Chromatographic system:** Proceed as directed in the Assay.

**Sensitivity solution and Sample solution:** Prepare as directed in *Organic Impurities, Procedure 1: Early-Eluting Impurities*.

**System suitability**

**Samples:** Standard solution and Sensitivity solution

**Suitability requirements**

**Tailing factor:** NMT 2.0, Standard solution

**Relative standard deviation:** NMT 2.0%, Standard solution

**Signal-to-noise ratio:** NLT 10, Sensitivity solution

**Analysis**

**Sample:** Sample solution

Calculate the percentage of each late-eluting impurity in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_u/r_s) \times (1/F_2) \times 100$$

$r_u$  = peak response of each individual impurity from the Sample solution

$r_s$  = peak response of fludarabine phosphate from the Sample solution

$F_2$  = relative response factor for each individual impurity (see [Table 2](#))

**Acceptance criteria:** See [Table 2](#).

**Table 2**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Fludarabine phosphate	1.0	—	—
2-Fluoroadenine <sup>a</sup>	1.5	2.0	0.1
2-Fluoro-ara-adenine <sup>b</sup>	1.9	1.7	0.2
2-Ethoxyphosphate analog <sup>c</sup>	2.5	0.56	0.2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Any individual, unspecified impurity	>1.0	1.0	0.1
Total unspecified impurities <sup>d</sup>	—	—	0.5
Total impurities <sup>e</sup>	—	—	1.5

<sup>a</sup> 2-Fluoro-9*H*-purin-6-amine.<sup>b</sup> 9- $\beta$ -D-Arabinofuranosyl-2-fluoroadenine.<sup>c</sup> 2-Ethoxy-9- $\beta$ -D-arabinofuranosyladenine 5'- (dihydrogen phosphate).<sup>d</sup> The sum of all unspecified impurities found in *Organic Impurities, Procedure 1: Early-Eluting Impurities* and *Organic Impurities, Procedure 2: Late-Eluting Impurities*.<sup>e</sup> The sum of all impurities found in *Organic Impurities, Procedure 1: Early-Eluting Impurities* and *Organic Impurities, Procedure 2: Late-Eluting Impurities*.

• **LIMIT OF ALCOHOL**

**Standard solution:** 0.50 mg/mL of [alcohol](#) in [dimethylformamide](#)

**Sample solution:** 50 mg/mL of Fludarabine Phosphate in [dimethylformamide](#)

**Blank:** [Dimethylformamide](#)

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** GC equipped with a headspace injector

**Detector:** Flame ionization

**Column:** 0.25-mm  $\times$  30-m; 1.4- $\mu$ m coating of phase [G43](#)

**Temperatures**

**Injection port:** 160°

**Detector:** 250°

**Column:** See [Table 3](#).

**Table 3**

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
40	0	40	10
40	5	70	—
70	30	220	—

**Carrier gas:** Helium

**Flow rate:** 27 cm/s

**Sample**

**Volume:** 2 mL/vial. [NOTE—Seal the vials using a flanged cap so that the cap can no longer be turned.]

**Conditioning temperature:** 80°

**Conditioning time:** 60 min

**Injection volume:** 1.0 mL

**System suitability**

**Samples:** Standard solution and Blank

[NOTE—The retention time for alcohol is about 3 min.]

**Suitability requirements**

**Relative standard deviation:** NMT 4.0% for three injections, Standard solution

**Peak interference:** No peak at the retention time for alcohol, Blank

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of alcohol in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak area of alcohol from the *Sample solution*

$r_s$  = peak area of alcohol from the *Standard solution*

$C_s$  = concentration of alcohol in the *Standard solution* (mg/mL)

$C_u$  = concentration of Fludarabine Phosphate in the *Sample solution* (mg/mL)

[NOTE—Use the percentage obtained to calculate the Assay result on the solvent-free basis.]

**Acceptance criteria:** NMT 1.0%

#### SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total aerobic microbial count is NMT  $10^3$  cfu/g.
- [OPTICAL ROTATION \(781S\), Procedures, Specific Rotation](#)

**Sample solution:** 5 mg/mL in water

**Acceptance criteria:** +10° to +14°

- [WATER DETERMINATION \(921\), Method I](#): NMT 3.0%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed, light-resistant containers, and store in a refrigerator.
- [USP REFERENCE STANDARDS \(11\)](#)  
[USP Fludarabine Phosphate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLUDARABINE PHOSPHATE	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 43(5)

**Current DocID:** [GUID-E55F42F8-8E2A-4536-A5EB-FB62EA29CFE4\\_6\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M33310\\_06\\_01](https://doi.org/10.31003/USPNF_M33310_06_01)

**DOI ref:** [ng941](#)